-- Study did not achieve its primary endpoint in first-of-its kind trial for patients suffering from life-threatening seizure condition --
Demographics and baseline characteristics were well-balanced between
treatment groups in the study. Due to the severity and complexity of
their underlying medical conditions, serious adverse events commonly
occur in patients with SRSE and were similar in frequency and type
between the two treatment groups. SRSE, a life-threatening persistent
state of seizure that does not respond to first-, second- or third-line
treatments, is a neurological emergency that may cause death or
life-altering outcomes. There are no treatments for SRSE currently
approved by the
"I'm proud of the Sage team for the significant progress they have made
in improving our understanding of how to best treat these critically ill
The STATUS Trial was conducted under a Special Protocol Assessment (SPA)
agreement with the
"SRSE is an extremely complicated condition to treat and there is a
significant unmet need for new treatments," said
Summary of Top-line Brexanolone Phase 3 STATUS Trial Results
Sage intends to present detailed results from the STATUS Trial at an upcoming medical meeting.
Conference Call Information
Sage will host a conference call and webcast today at
About Super-Refractory Status Epilepticus
Status epilepticus (SE) is an acute medical emergency of persistent, unremitting seizure lasting greater than five minutes. An SE patient is first treated with benzodiazepines, and if no response, is then treated with other, second-line, anti-seizure drugs. If the seizure persists after the second-line therapy, the patient is diagnosed as having refractory SE (RSE), admitted to the ICU and placed into a medically induced coma. Physicians typically use anesthetic agents to induce the coma, along with antiepileptic drugs in an attempt to stop the ongoing seizure, in RSE patients. After a period of 24 hours, an attempt is made to wean the patient from the anesthetic agents to evaluate whether or not the seizure condition has resolved. Unfortunately, not all patients respond to weaning attempts, in which case the patient must be maintained in the medically induced coma. At this point, the patient is diagnosed as having SRSE. Sage estimates that there are between 25,000 and 41,000 cases of SRSE in the
About the STATUS Trial
Sage designed the pivotal Phase 3 STATUS Trial to evaluate the efficacy and safety of brexanolone in patients with SRSE, ages two years or older, in the
About Brexanolone (SAGE-547)
Brexanolone is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors. Brexanolone is an intravenous agent that was evaluated as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE) in the global Phase 3 STATUS Trial. Brexanolone has been granted both Fast Track and orphan drug designations by the FDA for the treatment of SRSE.
Brexanolone is also being developed for the treatment of postpartum depression (PPD) and has been granted Breakthrough Therapy designation by the FDA and PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) in PPD. Sage is currently evaluating brexanolone in a Phase 3 development program for the treatment of PPD. For more information about these trials, please visit https://thehummingbirdstudy.com/.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547) completed a Phase 3 trial for super-refractory status epilepticus, a rare and severe seizure disorder, and is in Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.
Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: our expectations regarding the development of our product candidates and their potential in the treatment of various CNS disorders. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may not be able to generate supportive non-clinical or clinical data sufficient to continue clinical development or to successfully demonstrate the efficacy and safety of our product candidates at each stage of clinical development; success in our non-clinical studies or in earlier stage clinical trials may not be repeated or observed in ongoing or future studies involving the same compound or other product candidates; we may experience delays in enrollment of our clinical trials or the need for additional data; decisions or actions of regulatory agencies may affect the timing of our clinical trials or future regulatory submissions, and regulatory authorities may not agree with our interpretation of the results of our non-clinical and clinical studies, and may make decisions that negatively impact our ability to continue development or to gain approval, including the risk that regulatory authorities may, despite prior advice, decide that the clinical and non-clinical data from a development program are not sufficient to support approval; we may encounter unexpected adverse events or other safety issues related to any of our product candidates that may impact further development or our chances of obtaining regulatory approval; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates which may delay our timing or increase our expenses, as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
News Provided by Acquire Media